Patients who responded well to bevacizumab showed significantly increased CCL28 expression, and high expression of CCL28 in tumor cells,, was associated with enhanced vascular maturity and favorable treatment outcomes (Fig. 6D, 6E). The gene discussed is CCL28; the disease is neoplasm.